BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27374703)

  • 1. Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.
    Jo SY; Park SH; Kim IS; Yi J; Kim HH; Chang CL; Lee EY; Cho YU; Jang S; Park CJ; Chi HS
    Ann Lab Med; 2016 Sep; 36(5):399-404. PubMed ID: 27374703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
    Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
    Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype].
    Su L; Li W; Cui JW; Tan YH; Yang Y; Liu XL; Yu P; Hu RP; Wang LL; Gao SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):571-5. PubMed ID: 23815900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia.
    Park BG; Chi HS; Jang S; Park CJ; Kim DY; Lee JH; Lee JH; Lee KH
    Ann Hematol; 2013 Apr; 92(4):451-7. PubMed ID: 23238897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NPM1 mutation type has no impact on survival in cytogenetically normal AML.
    Pastore F; Greif PA; Schneider S; Ksienzyk B; Mellert G; Zellmeier E; Braess J; Sauerland CM; Heinecke A; Krug U; Berdel WE; Buechner T; Woermann B; Hiddemann W; Spiekermann K
    PLoS One; 2014; 9(10):e109759. PubMed ID: 25299584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia: 2013 update on risk-stratification and management.
    Estey EH
    Am J Hematol; 2013 Apr; 88(4):318-27. PubMed ID: 23526416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.
    Ottone T; Ammatuna E; Lavorgna S; Noguera NI; Buccisano F; Venditti A; Giannì L; Postorino M; Federici G; Amadori S; Lo-Coco F
    J Mol Diagn; 2008 May; 10(3):212-6. PubMed ID: 18403613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
    Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
    Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
    Schnittger S; Kern W; Tschulik C; Weiss T; Dicker F; Falini B; Haferlach C; Haferlach T
    Blood; 2009 Sep; 114(11):2220-31. PubMed ID: 19587375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
    How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
    Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
    Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
    Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Höllein A; Meggendorfer M; Dicker F; Jeromin S; Nadarajah N; Kern W; Haferlach C; Haferlach T
    Blood Adv; 2018 Nov; 2(22):3118-3125. PubMed ID: 30455361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M; Pillai R; Warita K; Mitsuhashi-Warita T; Mehta R; Boyiadzis M; Djokic M; Kant JA; Roth CG
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):212-7. PubMed ID: 22914610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
    Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
    Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I diagnose and treat NPM1-mutated AML.
    Falini B; Brunetti L; Martelli MP
    Blood; 2021 Feb; 137(5):589-599. PubMed ID: 33171486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.